Dr. Tim Allerton, an Assistant Professor and Director of the Vascular Metabolism Laboratory at LSU’s Pennington Biomedical Research Center, has recently been awarded a highly competitive National Institutes of Health (NIH) R01 grant. Valued at up to $3.6 million, this five-year funding will support pioneering research into heart failure with preserved ejection fraction (HFpEF), a rapidly growing and complex form of heart failure affecting millions of people worldwide.
Unlike traditional heart failure, HFpEF patients maintain normal cardiac ejection fractions, yet their hearts struggle to relax and fill effectively during diastole. This dysfunction leads to chronic symptoms such as fatigue and severely limited exercise capacity. Dr. Allerton’s groundbreaking prior research has demonstrated that in addition to cardiac impairments, abnormalities in skeletal muscle metabolism and vascular function significantly exacerbate these symptoms.
Central to Dr. Allerton’s new research is the role of hydrogen sulfide (H₂S), a gaseous signaling molecule with critical regulatory functions in cellular metabolism and vascular health. Evidence indicates that H₂S levels decline in HFpEF patients, disrupting mitochondrial energy production in skeletal muscle and impairing blood flow, both of which are essential for exercise performance. Dr. Allerton’s project aims to unravel how this decline drives muscle dysfunction and contributes to exercise intolerance in HFpEF.
An innovative aspect of this work involves testing a novel therapeutic approach that delivers hydrogen sulfide directly to mitochondria, the cell’s powerhouses responsible for energy generation. By restoring mitochondrial H₂S availability, the therapy seeks to improve muscle metabolism and enhance oxygen delivery during physical activity, potentially reversing some of the debilitating effects of HFpEF.
This research initiative integrates expertise across vascular biology, muscle metabolism, and exercise physiology to explore systemic contributors to heart failure, rather than focusing solely on cardiac function. The hope is to identify mechanisms that can be therapeutically targeted to improve quality of life for patients who currently have limited treatment options.
Heart failure with preserved ejection fraction is frequently associated with metabolic comorbidities such as obesity, hypertension, and type 2 diabetes. Exercise intolerance stands out as the strongest predictor of hospitalization and mortality in this population, underscoring the urgent need for effective interventions. Preclinical models have already shown promising improvements in muscle function and exercise capacity following H₂S restoration.
The NIH R01 grant represents one of the most competitive awards available for investigator-initiated biomedical research and recognizes the transformative potential of Dr. Allerton’s work. The research conducted through this funding is poised to significantly advance understanding of the pathophysiology of HFpEF and open doors to new, metabolism-focused treatments that improve vascular and skeletal muscle health.
By pioneering this novel therapeutic avenue, the study promises to shift the paradigm in heart failure care, addressing systemic dysfunctions that have long been overlooked and offering renewed hope to millions affected by this challenging condition.
Subject of Research: Heart failure with preserved ejection fraction (HFpEF) and hydrogen sulfide’s role in skeletal muscle and vascular function
Article Title: NIH Awards $3.6 Million to Investigate Hydrogen Sulfide Therapy for Heart Failure with Preserved Ejection Fraction
News Publication Date: Not specified
Web References:
- Pennington Biomedical Research Center – Vascular Metabolism Lab
- NIH RePORTER Project Details
Image Credits: PBRC
Keywords: HFpEF, heart failure, hydrogen sulfide, skeletal muscle metabolism, vascular function, mitochondrial therapy, NIH R01 grant, exercise intolerance
